Skip to content

The University of North Carolina at Chapel Hill

University Gazette

Pancreatic cancer treatment could increase life expectancy

Pancreatic cancer cells are notorious for being protected by a fortress of tissue, making it difficult to deliver drugs to either shrink the tumor or stop its growth. Now Carolina researchers have developed a device that could change all that: By using electric fields, the device can drive chemotherapy drugs directly into tumors, preventing their growth and in some cases, shrinking them.

The work, which was published Feb. 4 in Science Translational Medicine, opens the possibility of dramatically increasing the number of people who are eligible for life-saving surgeries. It represents a fundamentally new treatment approach for pancreatic cancer, which has a 75 percent mortality rate within a year of diagnosis – a statistic that has not changed in more than 40 years.


“Surgery to remove a tumor currently provides the best chance to cure pancreatic cancer,” said Joe DeSimone, Chancellor’s Eminent Professor of Chemistry at UNC and William R. Kenan, Jr. Distinguished Professor of Chemical Engineering at N.C. State. “However, often a diagnosis comes too late for a patient to be eligible for surgery due to the tendency of the tumors to become intertwined with major organs and blood vessels.”

Jen Jen Yeh, associate professor of surgery and pharmacology in the School of Medicine, described the device’s potential: “Once this goes to clinical trials, it could shift the paradigm for pancreatic cancer treatments – or any other solid tumors where standard IV chemotherapy drugs are hard to get to.” She also is a member of the Lineberger Comprehensive Cancer Center.

James Byrne, a member of DeSimone’s lab at Carolina, led the research by constructing the device and examining its ability to deliver chemotherapeutic drugs effectively to pancreatic cancer tumors, as well as two types of breast cancer tumors.

Depending on the tumor type, the new device can be used either internally after a minimally invasive surgery to implant the device’s electrodes directly on a tumor (an approach relevant especially for pancreatic cancer and other less accessible tumors) or externally to deliver drugs through the skin (an approach relevant especially for treating inflammatory breast cancers and other accessible tumors such as head and neck cancers).


Compared to a control (left), mice treated with a chemotherapy drug using the device experienced significant growth reduction as confirmed by the lack of brown staining for a marker of tumor growth.

Researchers have also demonstrated the device’s ability to enable higher drug concentrations in tumor tissue while avoiding increased systemic toxicity. This is especially important in treating pancreatic and other solid tumors, which are more difficult to reach using standard treatment methods that rely on the bloodstream for delivering cancer-fighting drugs to tumors.

“Progress in the treatment of pancreatic cancer has been persistent but incremental in the past few decades, relying largely on advances in drug therapies. To our knowledge, our study represents the first time iontophoresis has been applied to target pancreatic cancer,” said Byrne, who is currently completing his medical degree at Carolina after earning his doctorate in 2014.

“We hope our invention can be used in humans in the coming years and result in a notable increase in life expectancy and quality among patients diagnosed with pancreatic and other types of cancer,” he added.

The work was funded in part by the University Cancer Research Fund and the National Institutes of Health’s Director’s Pioneer Award Program. Collaboration among researchers at Carolina’s Eshelman School of Pharmacy, School of Medicine, Lineberger Comprehensive Cancer Center and College of Arts and Sciences made the work possible.